TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00460317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 706
Description: 125 mg QD orally every day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 125 mg QD orally every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: 200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
Study: NCT03068013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM
Description: CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPI
Description: Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
Study: NCT00005881

Intervention type: OTHER
Intervention: Quality of Life Forms
Description: Completion of the instrument \[Minneapolis-Manchester Quality of Life (MM-QOL)\] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
Study: NCT03719053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
Study: NCT03066622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care as per attending physician
Description: Patients are randomized to standard of care medication (as determined by attending physician)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg rapidly dissolving olanzapine
Description: 5mg rapidly dissolving olanzapine
Study: NCT03380793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morinidazole
Description: morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
Study: NCT02916797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepping training with feedback
Description: Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
Study: NCT03486925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin (24IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo
Study: NCT03539367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT01598402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanic acid suspension
Description: 625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
Study: NCT03983993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study: NCT00860067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q/LAIV (MEDI3250)
Description: 0.2 mL dose at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist/B/Yamagata
Description: 0.2 mL dose at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist/B/Victoria
Description: 0.2 mL dose at Day 0
Study: NCT01316341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: patient to receive a tablet containing high dose BI10773 p.o. plus one placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patient to receive two placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patient to receive two placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patient to receive two placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
Study: NCT02289547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: maintenance capecitabine therapy after six cycles of XELOX
Study: NCT04745494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OT administration
Description: OT nasal administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Placebo nasal administration
Study: NCT04822480

Intervention type: BEHAVIORAL
Intervention: Diabetes Prevention Program (DPP)
Description: Individuals with prediabetes can mitigate the risks and costs of diabetes by taking preventative action, such as participation in a National Diabetes Prevention Program (DPP). The DPP began as a multisite randomized controlled trial demonstrating the effectiveness and cost-benefit of a 12-month intensive lifestyle intervention over pharmaceutical treatment for preventing or delaying diabetes among prediabetic participants. In 2010, Congress authorized the Centers for Disease Control and Prevention to lead the dissemination of the DPP as a targeted approach (high risk populations) and population-based strategy to reduce the incidence of diabetes and diabetes-related healthcare costs. The goal is to achieve modest weight loss (7%) by developing and implementing behavior change skills resulting in lifestyle modifications such as physical activity (150 minutes per week) and dietary and nutritional practices.
Study: NCT02756832

Intervention type: DRUG
Intervention: Alogliptin Benzoate
Description: Alogliptin benzoate tablets
Study: NCT00310323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 0.5 mg/kg (maximum 30 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Administered as 4 ounces of Coca-Cola
Study: NCT04432714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
Study: NCT01540565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT02724722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned intervention
Description: a simple flyer plus face-to-face health education and give one bag containing stainless steel-made tableware for eating out use

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: a simple flyer only with no face-to-face health education and give one bag not containing stainless steel-made tableware for eating out use
Study: NCT01115985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: oral
Study: NCT03548116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ultrasound
Description: A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ultrasound
Description: A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ultrasound
Description: A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
Study: NCT03739775

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.
Study: NCT00920621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 cholecalciferol
Description: Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000 IU of vitamin D3 administered orally once a day during pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 4000 IU of vitamin D3 administered orally once a day during pregnancy
Study: NCT01222468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nabilone 0.5 mg
Description: nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
Study: NCT04386226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ambrotose LIFE
Description: Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.
Study: NCT04432714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2，IV, d0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 50 mg/m2/day CI24h d1-d4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 10 mg/m2/day CI24h d1-d4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 0.4mg/m2/day CI24h d1-d4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2/day IV d5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60 mg/m2/bid oral or IV d1-d5
Study: NCT02894125

Intervention type: OTHER
Intervention: SPA Therapy
Study: NCT04303026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: 5mg IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Placebo Group. Saline 0.9% 100 ml infusion
Study: NCT03580109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate spa treatment
Description: Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Late spa treatment
Description: Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
Study: NCT02180295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212 Lot 1
Description: Inactivated Varicella Zoster Virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212 Lot 2
Description: Inactivated Varicella Zoster Virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212 Lot 3
Description: Inactivated Varicella Zoster Virus vaccine
Study: NCT05524896

Intervention type: DEVICE
Intervention: ElucidVivo
Description: Plaque morphology characterization for predicting non-invasive fractional flow reserve (FFR)

Intervention type: DEVICE
Intervention: ElucidVivo
Description: Plaque morphology characterization for predicting non-invasive fractional flow reserve (FFR)
Study: NCT01023256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR103
Description: MOR103 0.3 mg/kg or placebo iv x 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR103
Description: MOR103 1.0 mg/kg or placebo iv x 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR103
Description: MOR103 1.5 mg/kg or placebo iv x 4 doses
Study: NCT03177031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stay Safe Link (SSL)
Description: CAPD system produced in Malaysia by Fresenius Medical Care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stay Safe (STS)
Description: CAPD system produce in Germany by Fresenius Medical Care
Study: NCT04692480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Video Education
Description: Video entitled Breastfeeding in the First Hour, It's in Your Hands

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding PDF education
Description: PDF of standard breastfeeding education handouts
Study: NCT03943264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPro1595
Description: XPro1595 will be delivered by subcutaneous injection once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPro1595
Description: XPro1595 will be delivered by subcutaneous injection once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPro1595
Description: XPro1595 will be delivered by subcutaneous injection once a week
Study: NCT02199353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation of Activities Daily Living
Description: Experimental group: SADL programme which is a new treatment approach created by the authors of this study for the training of ADL through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ADLOccupational Therapy
Description: Control group treatment: conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks.
Study: NCT03111472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management guide for people with Parkinson's who fall and their informal caregivers
Description: The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.
Study: NCT04386226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ambrotose LIFE
Description: Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Ambrotose
Description: Advanced Ambrotose contains aloe vera extract inner leaf gel, arabinogalactan, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, and rice starch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Ambrotose
Description: Advanced Ambrotose contains aloe vera extract inner leaf gel, arabinogalactan, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, and rice starch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT00545350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall prevention exercise program
Description: Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.~The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises.
Study: NCT03428672

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: total hip arthroplasty
Description: Bone samples from Hip fracture were collected from the femoral head which has been replaced

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total hip arthroplasty
Description: Bone samples from Hip fracture were collected from the femoral head which has been replaced
Study: NCT00790231

Intervention type: DEVICE
Intervention: urodynamic procedure
Description: introduction of the urodynamic catheter into the bladder and assessment of the bladder function

Intervention type: DEVICE
Intervention: urodynamic procedure
Description: introduction of the urodynamic catheter into the bladder and assessment of the bladder function
Study: NCT04284930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depobupivacaine
Description: surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnQ pump
Description: group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
Study: NCT04510506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas (AP)
Description: The AP system used in this trial is the Tandem t:slim insulin pump with Control-IQ Technology. This system is FDA approved for use starting at age 14 years.
Study: NCT00055770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00804102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcorneal Electrical Stimulation
Description: Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DTL-electrode attached without energy
Description: DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.